Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;9(2):83-88.
doi: 10.1016/j.ijpam.2021.02.007. Epub 2021 Mar 3.

Treatment of hyperglycemia not associated with NAFLD improvement in children with type 2 diabetes mellitus

Giovanna Beauchamp  1 , Mary M Barr  1 , Ariana Vergara  2 , Ambika Ashraf  1 , Fernando Bril  2   3
Affiliations

Treatment of hyperglycemia not associated with NAFLD improvement in children with type 2 diabetes mellitus

Giovanna Beauchamp et al. Int J Pediatr Adolesc Med. 2022 Jun.

Abstract

Background and objectives: Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) have become public health problems in the pediatric population. However, the relationship between these two conditions is not well understood. The primary objective of this study was to assess whether treatment of hyperglycemia in obese, treatment-naive children with type 2 diabetes (T2DM) was associated with an improvement of surrogate markers of NAFLD.

Materials and methods: This retrospective, longitudinal study included 151 obese children with a diagnosis of T2DM (Age: 14 ± 1 years, 72% female children, BMI: 98.6th percentile, and A1c: 10.3 ± 0.2%). Clinical/demographic information was collected before patients started any diabetes treatment and 1 and 3 years after starting metformin and/or insulin therapy.

Results: Forty-eight patients (32%) had abnormal ALT/AST (i.e., >40 U/L), suggestive of NAFLD. After 1 year of therapy, there were no significant differences in plasma ALT among patients started on insulin, metformin, or combination: 5±4 vs. -10 ± 3 vs. -2±2 IU/L, respectively, P = .07. Of note, changes in plasma ALT were small, despite a significant reduction of A1c in patients prescribed insulin (alone or with metformin): -2.8 ± 1.0%, P = .01, and -2.7 ± 0.3%, P < .001, respectively. In line with this, no significant correlations were found between changes in A1c and plasma aminotransferases. In contrast, changes in plasma AST/ALT were more strongly associated with BMI changes (r = 0.32, P < .001, and r = 0.19, P = .04, respectively). Similar results were observed after 3 years of follow-up.

Conclusions: Nonalcoholic fatty liver disease is highly prevalent in obese children with T2DM. Treatment of hyperglycemia with metformin and/or insulin did not result in any significant improvement in surrogate markers of NAFLD (i.e., plasma aminotransferases). While changes in ALT and/or AST may not perfectly reflect histological changes in NAFLD, our findings suggest that the treatment of hyperglycemia per se may not be associated with NAFLD improvement.

Keywords: Fatty liver; Insulin resistance; Insulin therapy; Metformin; Steatosis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Relative Changes in Plasma ALT and AST Over Time After Diagnosis of Type 2 Diabetes Mellitus.
Fig. 2
Fig. 2
Changes in A1c After the Diagnosis of Type 2 Diabetes Mellitus Based on Treatment Prescribed.
See this image and copyright information in PMC

References

    1. Bril F., Cusi K. Nonalcoholic fatty liver disease: the new complication of type 2 diabetes mellitus. Endocrinol Metab Clin N Am. 2016;45:765–781. - PubMed
    1. Younossi Z., Tacke F., Arrese M., Sharma B.C., Mostafa I., Bugianesi E., et al. Global perspectives on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Hepatology. 2019;69:2672–2682. - PubMed
    1. Yu E.L., Golshan S., Harlow K.E., Angeles J.E., Durelle J., Goyal N.P., et al. Prevalence of nonalcoholic fatty liver disease in children with obesity. J Pediatr. 2019;207:64–70. - PMC - PubMed
    1. Schwimmer J.B., Behling C., Newbury R., Deutsch R., Nievergelt C., Schork N.J., et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology. 2005;42:641–649. - PubMed
    1. Newton K.P., Hou J., Crimmins N.A., Lavine J.E., Barlow S.E., Xanthakos S.A., et al. Prevalence of prediabetes and type 2 diabetes in children with nonalcoholic fatty liver disease. JAMA Pediatr. 2016;170 - PMC - PubMed